News

A steering committee has put a phase IIB/III study of desmoteplase on hold until further data have been analyzed. The study is evaluating the effects of desmoteplase in

TNX-650 has a mechanism of action unique from currently available asthma treatments and has the potential to be a therapeutic option for patients whose disease is not currently

In December 2005, Wyeth and Progenics entered into a collaboration to develop methylnaltrexone. Under the terms of the agreement, Progenics has the potential to receive as much as

<p>The injunction has been granted prior to a final court decision on the validity of the patent. <br /><br />The preliminary injunction will be in effect until the

The new Nexium formulation is an oral suspension product and will be an alternative to Nexium tablets. This new oral suspension version of Nexium contains esomeprazole, the same

Upon completion of the transaction of its biotech businesses, Cambrex said that it will concentrate on deploying its resources to maximize the potential of its human health business

The research could be significant for the treatment of Crohn's disease as Tysabri may be alternative to the anti-TNF class as patients remain in remission over a long

The objectives of this trial are to assess the safety, tolerability, pharmacokinetic profile and antiviral activity of HCV-796. The trial will asses HCV-796 when used in combination with

MD Anderson joins the University of Vermont and Scott & White Memorial Hospital in the trial which began treating patients in May 2006. MD Anderson has joined research